• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / U.S. Equity

These 4 Small Biotechs Have Big Upcoming Catalysts

Zogenix, Flexion, Dynavax and Progenics all have potential upside on these events.
By BRET JENSEN
Sep 30, 2017 | 02:00 PM EDT
Stocks quotes in this article: ZGNX, FLXN, DVAX, PGNX

The biotech sector continues to be mired in a tight trading range as we close out September, still digesting the nice gains from late in August. Individual small-cap names within the industry are still making big moves on company-specific news. If you are a shareholder of Zogenix, Inc.  (ZGNX) , a name I have mentioned a few times over the years, you are closing out the week on a winning note. The company just announced that its primary drug candidate met its primary and all secondary endpoints, in a much-anticipated Phase III trial for the treatment of the rare disease, Dravet's Syndrome. The shares were up some 120% in early trading.

So what other small-cap biotech and biopharma names could move upward on upcoming catalysts? Let's take a brief look at a couple.

Flexion Therapeutics (FLXN) is a name I have talked about several times over the past few months. The stock has moved from the high teens to mid $20s since June, in anticipation of an Oct. 6 PDUFA date for its primary drug candidate, Zilretta, which is seeking approval to treat osteoarthritis in the knee. Based on trial results, approval appears very likely. I think the shares move into the high $20s, perhaps even the low $30s if the compound gets the FDA's green light, as expected.

Dynavax Technologies (DVAX) has quadrupled off its lows early in the year to just over $20 a share. The main trigger was an overwhelming Ad Comm recommendation for approval of its hepatitis B vaccine, Heplisav-B, late in July. Its PDUFA date was postponed until Nov. 10 to allow time for the company to design a post-trial marketing study to cross the last 'I' before expected approval. I think the stock trades into the mid $20s once Heplisav-B gets the FDA's official blessing.

I also expect some sort of market and distribution deal to be announced soon after approval, at least for the rights to Heplisav-B outside the United States. This would boost the rollout effort and address any funding overhang remaining on the company. Finally, shareholders can expect some mid-stage trial results from a promising oncology asset, SD-101, in Dynavax's pipeline in the first half of 2018. All in all, I think shareholders will continue to be rewarded for their patience in this name.

Finally, we have Progenics Pharmaceuticals (PGNX) . The stock gave up all of its ~120% post-election rally and fell back down to just over $5.00 a share in early August. Most of the pullback was triggered by worries that its drug candidate Azedra's approval chances were low. I don't think that is the case, although I do think management could have done a better job explaining data from key trials around this compound, which targets two very rare cancers of the adrenal gland. The company has started to do that, including at this week's health care conference hosted by Cantor Fitzgerald. The stock has started to recover as a result. I expect shares to climb back into the low teens once Azedra is approved in the first half of 2018.

That wraps up a look at a few small biotechs that I think have upside on upcoming catalysts.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity

More from U.S. Equity

It Is Almost Buying Time Again: Here's My Shopping List

Peter Tchir
Mar 8, 2021 11:30 AM EST

I still really like AAA-rated CLO ETFs.

Index Charts 'Hammer' Out Improvement

Guy Ortmann
Mar 8, 2021 10:36 AM EST

The market's psychology basket remains cautionary as insiders continue selling.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

Climb This REIT for a 7%+ Dividend Yield

Bob Ciura
Mar 5, 2021 11:30 AM EST

Given historically low interest rates, REITs are the place where investors can search for high dividend yields.

No Market for Old Stock Pickers

James "Rev Shark" DePorre
Mar 5, 2021 10:58 AM EST

It doesn't matter if a stock is an exceptional value, has a great story, or an upcoming catalyst right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login